Literature DB >> 9507816

The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer.

W J Ellis1, R L Vessella, E Corey, E W Arfman, M M Oswin, S Melchior, P H Lange.   

Abstract

PURPOSE: The reverse transcriptase polymerase chain reaction (RT-PCR) assay is an extremely sensitive technique of detecting cells expressing prostate specific antigen (PSA). Controversy exists regarding the ability of peripheral blood PSA RT-PCR testing to reflect pathological staging or treatment outcome. We examine the phenomenology of RT-PCR results in patients with prostate cancer, with particular emphasis on the RT-PCR test before and after radical prostatectomy, and correlations with pathological staging and treatment outcome.
MATERIALS AND METHODS: Peripheral blood was obtained from a wide variety of patients with and without prostate cancer, including before and after radical prostatectomy. After ribonucleic acid isolation, complementary deoxyribonucleic acid was generated and amplified with a hot-start technique. RT-PCR results were compared with pathological stage, Gleason score, tumor volume and disease-free status. Correlations between preoperative and postoperative RT-PCR tests were also made.
RESULTS: The RT-PCR test was positive in 1 of 56 controls (1.8%) without suspicion of prostate cancer. A positive test was obtained in 12 of 65 men (18.5%) with a suspicion of prostate cancer but a negative biopsy. Before radical prostatectomy a positive test was obtained in 13 of 75 men (17.3%) with pT2 disease versus 10 of 46 (21.7%) with pT3 disease. There was no significant difference in serum PSA, Gleason score or tumor volume between the men with positive or negative results. With repetitive testing an increasing percentage of men had at least 1 positive test preoperatively. With a median followup of 8 months 6 of the 7 patients in whom radical prostatectomy failed had had negative RT-PCR before treatment. Of patients with known metastatic disease or failed primary treatment a positive test was obtained in 32 to 75%. Radical prostatectomy and prostate needle biopsy appeared to have a negligible effect on RT-PCR tests immediately following these procedures. Following radical prostatectomy results were variable but many men who are RT-PCR positive preoperatively become RT-PCR negative postoperatively.
CONCLUSIONS: The PSA RT-PCR test in our laboratory cannot be used preoperatively to predict pathological stage of prostate cancer or treatment failure. Most cases that are positive preoperatively become negative postoperatively. While increasing tumor burden increases the likelihood of positive tests, there appears to be significant sampling error associated with the use of this test in the peripheral blood.

Entities:  

Mesh:

Year:  1998        PMID: 9507816

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Peripheral blood rt-PCR assays for detection and prognosis of prostate cancer.

Authors:  Shahrokh F Shariat; Kevin M Slawin
Journal:  Rev Urol       Date:  2003

2.  The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer.

Authors:  Tracey L Krupski; George J Stukenborg; Kihyuck Moon; Dan Theodorescu
Journal:  BJU Int       Date:  2010-11       Impact factor: 5.588

3.  Twenty Years of PSA: From Prostate Antigen to Tumor Marker.

Authors:  Gabriela De Angelis; Harry G Rittenhouse; Stephen D Mikolajczyk; L Blair Shamel; Axel Semjonow
Journal:  Rev Urol       Date:  2007

4.  Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer.

Authors:  Constantine S Mitsiades; Peter Lembessis; Antigone Sourla; Constantine Milathianakis; Athanassios Tsintavis; Michael Koutsilieris
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

5.  Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.

Authors:  Pauliina Helo; Angel M Cronin; Daniel C Danila; Sven Wenske; Rita Gonzalez-Espinoza; Aseem Anand; Michael Koscuiszka; Riina-Minna Väänänen; Kim Pettersson; Felix K-H Chun; Thomas Steuber; Hartwig Huland; Bertrand D Guillonneau; James A Eastham; Peter T Scardino; Martin Fleisher; Howard I Scher; Hans Lilja
Journal:  Clin Chem       Date:  2009-02-20       Impact factor: 8.327

Review 6.  Detection and isolation of circulating tumor cells in urologic cancers: a review.

Authors:  Robert D Loberg; Yaron Fridman; Brian A Pienta; Evan T Keller; Laurie K McCauley; Russell S Taichman; Kenneth J Pienta
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

7.  Quantification of PSA mRNA levels in peripheral blood of patients with localized prostate adenocarcinoma before, during, and after radical prostatectomy by quantitative real-time PCR (qRT-PCR).

Authors:  Nadir Kalfazade; Ahmet M Kuskucu; Serdar Karadag; Selcuk Sahin; Bekir Aras; Kenan Midilli; Gülden Yilmaz; Ali I Tasci
Journal:  Int Urol Nephrol       Date:  2008-06-27       Impact factor: 2.370

Review 8.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

9.  Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients.

Authors:  Ilona N Holcomb; Douglas I Grove; Martin Kinnunen; Cynthia L Friedman; Ian S Gallaher; Todd M Morgan; Cassandra L Sather; Jeffrey J Delrow; Peter S Nelson; Paul H Lange; William J Ellis; Lawrence D True; Janet M Young; Li Hsu; Barbara J Trask; Robert L Vessella
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

Review 10.  When Prostate Cancer Circulates in the Bloodstream.

Authors:  Virginie Vlaeminck-Guillem
Journal:  Diagnostics (Basel)       Date:  2015-10-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.